EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The U.S. Food and Drug Administration in August granted accelerated approval to seladelpar, which the Foster City, Calif., company markets as Livdelzi. The drug was the key asset in Gilead's $4.3 ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

Earlier this year, the FDA accelerated approval of seladelpar for the treatment of primary biliary cholangitis (PBC), in ...